Venous Thromboembolism (VTE) Prevention
Canberra Hospital and Health ServicesClinical ProcedureVenous Thromboembolism (VTE) PreventionContents TOC \h \z \t "Heading 1,1,Heading 2,2" Contents PAGEREF _Toc491690680 \h 1Purpose PAGEREF _Toc491690681 \h 2Alerts PAGEREF _Toc491690682 \h 2Scope PAGEREF _Toc491690683 \h 2Section 1 – VTE Prevention PAGEREF _Toc491690684 \h 21.Risk Assessment PAGEREF _Toc491690685 \h 22.Prophylaxis Prescribing PAGEREF _Toc491690686 \h 33.Prophylaxis Administration PAGEREF _Toc491690687 \h 44.Patient Education PAGEREF _Toc491690688 \h 4Section 2 – VTE Prevention: Children PAGEREF _Toc491690689 \h 5Implementation PAGEREF _Toc491690690 \h 6Related Policies, Procedures, Guidelines and Legislation PAGEREF _Toc491690691 \h 6References PAGEREF _Toc491690692 \h 6Definition of Terms: Abbreviations PAGEREF _Toc491690693 \h 6Search Terms PAGEREF _Toc491690694 \h 6Attachments PAGEREF _Toc491690695 \h 7Attachment 1: Venous Thromboembolism Prophylaxis Guidelines PAGEREF _Toc491690696 \h 8Attachment 2: “Stop the Clot” Patient Brochure PAGEREF _Toc491690697 \h 12PurposeThe purpose of this procedure is to:Provide guidance to clinicians on the appropriate use of thromboprophylaxis Specify procedures to be followed to identify patients in need of thromboprophylaxis.Back to Table of Contents ScopeAlertsVenous thromboembolism is a serious risk to acutely unwell patients, being a well recognised cause for morbidity and mortality related to hospitalisation, immobilisation, medical illness or surgical procedures. This risk can be reduced with the use of prophylactic measures according to identified risk assessment.Back to Table of Contents ScopeThe Procedure will be applied to all patients admitted to Canberra Hospital. It describes the procedures by which members of the clinical staff will undertake a venous thromboembolism risk assessment and consider appropriate prophylactic measures.For information on Anticoagulation medications and management, see the Anticoagulation Procedure.Back to Table of Contents Section 1 – VTE PreventionProcedure Risk AssessmentAll patients will have their VTE risk assessed within 24 hours of hospital admission. The risk assessment must be carried out by a medical officer.The risk assessment will be carried out according to the Venous Thromboembolism Prophylaxis Guidelines (Attachment 1) which can be found in the bedside folder of every patient. More detailed prophylaxis guidelines for obstetric patients (both inpatient and outpatient) are provided in the CHHS Anticoagulation Management Clinical Procedure-Section 9The medical officer who conducts the risk assessment will document the risk assessment outcome, and any contraindications identified to either pharmacological or mechanical prophylaxis, on the VTE Prophylaxis section of the National Inpatient Medication Chart (NIMC).VTE risk needs to be assessed and documented weekly, or when the patient’s condition changes, on the medication chart.Any discrepancies between clinicians risk assessment must be discussed with the managing team.Prophylaxis PrescribingPharmacological ProphylaxisMedical Officers will prescribe appropriate VTE prophylaxis using the Venous Thromboembolism (VTE) Risk Assessment and Prophylaxis Guide (Attachment 1) and risk assessment results.Pharmacological prophylaxis will be prescribed on the ‘Medication’ field of the VTE Prophylaxis section on the patient’s medication chart.If pharmacological prophylaxis is contraindicated, clear documentation on the VTE prophylaxis section on the patient’s medication chart and in the patient’s medical record is required, along with the reason for the contraindication.Pharmacists will review the prophylaxis prescription using the Venous Thromboembolism(VTE) Risk Assessment and Prophylaxis Guide (Attachment 1) and risk assessment results and ensure any discrepancies are discussed with the managing team.Mechanical ProphylaxisMedical Officers will assess the need for mechanical prophylaxis using the Venous Thromboembolism (VTE) Risk Assessment and Prophylaxis Guide (Attachment 1) and risk assessment results. Mechanical prophylaxis requirements will be documented on the ‘Mechanical Prophylaxis’ field of the VTE Prophylaxis section on the patient’s medication If mechanical prophylaxis is contraindicated, clear documentation on the VTE Prophylaxis section the patient’s medication chart and in the patient’s medical record is required, along with the reason for the contraindication.Prophylaxis AdministrationNursing staff will administer pharmacological prophylaxis according to the medication prescription on the VTE Prophylaxis section on the patients medication chart and document the administration. Nursing staff will apply appropriate mechanical prophylaxis and document the application and checking (twice daily, once in the AM and once in the PM) on the VTE Prophylaxis section of the patient’s medication chart.Patient EducationNursing staff, Pharmacists and Medical Officers will provide education to patients and carers to help raise awareness of the importance of VTE prevention, describe the treatments to prevent VTE and outline what patients should do to reduce risk both during admission and upon discharge.A patient information brochure “Blood Clots: Reducing your Risk” is available in English from the National Health and Medical Research Council website: HYPERLINK "" . The consumer brochure is also available in 13 other languages: Arabic, Chinese, Croatian, French, Greek, Italian, Macedonian, Polish, Russian, Serbian, Spanish, Turkish and Vietnamese at the following site: Attachment 2 for the information Brochure.Reassessing Risk at Discharge and Continuity of CarePatients who have been identified as being at risk of VTE during their admission are required to be reassessed at the point of discharge to determine if there is a need for extended prophylaxis. The recommended duration of pharmacological prophylaxis depends on the patient’s medical and mobility status as per the Venous Thromboembolism Prophylaxis Guidelines (Attachment 1).Patients who require extended prophylaxis should have a thorough plan handed over from the assessing medical officer to the patient’s continuing care provider, and this should be explained to patients and carers. Further information on appropriate clinical handover can be found in the Clinical Handover Procedure. Prior to discharge home or to another care facility, an ongoing supply of required prophylaxis should be organised to ensure uninterrupted treatment. Plans relating to the continued supply of prophylaxis once discharged should be clearly communicated to patients and carers. The patient should understand the reason for and importance of continued prophylaxis and the plan for its continuation. Back to Table of Contents Section 2 – VTE Prevention: ChildrenIn general children are at extremely low risk of VTE. Specific prophylaxis is rarely required in the paediatric population.Early mobilisation and adequate hydration should be routinely practiced to minimise the risk of VTE. However, VTE does occasionally occur in paediatric patients and paediatric patients at risk should be considered for VTE thromboprophylaxisPEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TdGVpbjwvQXV0aG9yPjxZZWFyPjIwMDQ8L1llYXI+PFJl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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TdGVpbjwvQXV0aG9yPjxZZWFyPjIwMDQ8L1llYXI+PFJl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ADDIN EN.CITE.DATA 1-3.Mechanical thromboembolism prophylaxis is not recommended ADDIN EN.CITE <EndNote><Cite><Author>Westmead</Author><Year>2010</Year><RecNum>237</RecNum><DisplayText><style face="superscript">2</style></DisplayText><record><rec-number>237</rec-number><foreign-keys><key app="EN" db-id="pseax52au2spagesfz55ssrxezptref2pzex">237</key></foreign-keys><ref-type name="Government Document">46</ref-type><contributors><authors><author>The Children's Hospital at Westmead</author></authors><secondary-authors><author>NSW Health</author></secondary-authors></contributors><titles><title>THROMBOPROPHYLAXIS IN SURGICAL AND TRAUMA PAEDIATRIC PATIENTS 
PRACTICE GUIDELINE</title></titles><dates><year>2010</year></dates><publisher>NSW Health</publisher><urls></urls></record></Cite></EndNote>2.Low molecular weight heparin (LMWH) is recommended for VTE prophylaxis for high risk paediatric patients.Procedure Paediatric patients at high risk of VTE should be identified using the following guidelinesPEVuZE5vdGU+PENpdGU+PEF1dGhvcj5XZXN0bWVhZDwvQXV0aG9yPjxZZWFyPjIwMTA8L1llYXI+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=
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5XZXN0bWVhZDwvQXV0aG9yPjxZZWFyPjIwMTA8L1llYXI+
PFJlY051bT4yMzc8L1JlY051bT48RGlzcGxheVRleHQ+PHN0eWxlIGZhY2U9InN1cGVyc2NyaXB0
Ij4yLDQ8L3N0eWxlPjwvRGlzcGxheVRleHQ+PHJlY29yZD48cmVjLW51bWJlcj4yMzc8L3JlYy1u
dW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJwc2VheDUyYXUyc3BhZ2Vz
Zno1NXNzcnhlenB0cmVmMnB6ZXgiPjIzNzwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBu
YW1lPSJHb3Zlcm5tZW50IERvY3VtZW50Ij40NjwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0
aG9ycz48YXV0aG9yPlRoZSBDaGlsZHJlbiZhcG9zO3MgSG9zcGl0YWwgYXQgV2VzdG1lYWQ8L2F1
dGhvcj48L2F1dGhvcnM+PHNlY29uZGFyeS1hdXRob3JzPjxhdXRob3I+TlNXIEhlYWx0aDwvYXV0
aG9yPjwvc2Vjb25kYXJ5LWF1dGhvcnM+PC9jb250cmlidXRvcnM+PHRpdGxlcz48dGl0bGU+VEhS
T01CT1BST1BIWUxBWElTIElOIFNVUkdJQ0FMIEFORCBUUkFVTUEgUEFFRElBVFJJQyBQQVRJRU5U
UyAmI3hEO1BSQUNUSUNFIEdVSURFTElORTwvdGl0bGU+PC90aXRsZXM+PGRhdGVzPjx5ZWFyPjIw
MTA8L3llYXI+PC9kYXRlcz48cHVibGlzaGVyPk5TVyBIZWFsdGg8L3B1Ymxpc2hlcj48dXJscz48
L3VybHM+PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+SmFja3NvbjwvQXV0aG9yPjxZZWFy
PjIwMDg8L1llYXI+PFJlY051bT4yNDA8L1JlY051bT48cmVjb3JkPjxyZWMtbnVtYmVyPjI0MDwv
cmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9InBzZWF4NTJhdTJz
cGFnZXNmejU1c3NyeGV6cHRyZWYycHpleCI+MjQwPC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10
eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1
dGhvcnM+PGF1dGhvcj5KYWNrc29uLCBQLiBDLjwvYXV0aG9yPjxhdXRob3I+TW9yZ2FuLCBKLiBN
LjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPkFuYWVzdGhl
dGljIERlcGFydG1lbnQsIFNoZWZmaWVsZCBDaGlsZHJlbiZhcG9zO3MgTkhTIFRydXN0LCBXZXN0
ZXJuIEJhbmssIFNoZWZmaWVsZCwgVUsuPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+UGVy
aW9wZXJhdGl2ZSB0aHJvbWJvcHJvcGh5bGF4aXMgaW4gY2hpbGRyZW46IGRldmVsb3BtZW50IG9m
IGEgZ3VpZGVsaW5lIGZvciBtYW5hZ2VtZW50PC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPlBhZWRp
YXRyIEFuYWVzdGg8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10
aXRsZT5QYWVkaWF0ciBBbmFlc3RoPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+NDc4
LTg3PC9wYWdlcz48dm9sdW1lPjE4PC92b2x1bWU+PG51bWJlcj42PC9udW1iZXI+PGVkaXRpb24+
MjAwOC8wNS8wMTwvZWRpdGlvbj48a2V5d29yZHM+PGtleXdvcmQ+QWRvbGVzY2VudDwva2V5d29y
ZD48a2V5d29yZD5BbmVzdGhlc2lvbG9neS8gc3RhbmRhcmRzPC9rZXl3b3JkPjxrZXl3b3JkPkNh
dGhldGVyaXphdGlvbiwgQ2VudHJhbCBWZW5vdXMvIGFkdmVyc2UgZWZmZWN0czwva2V5d29yZD48
a2V5d29yZD5DaGlsZDwva2V5d29yZD48a2V5d29yZD5DaGlsZCwgUHJlc2Nob29sPC9rZXl3b3Jk
PjxrZXl3b3JkPkZlbWFsZTwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdv
cmQ+SW5mYW50PC9rZXl3b3JkPjxrZXl3b3JkPk1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+UGVyaW9w
ZXJhdGl2ZSBDYXJlPC9rZXl3b3JkPjxrZXl3b3JkPlByYWN0aWNlIEd1aWRlbGluZXMgYXMgVG9w
aWMvIHN0YW5kYXJkczwva2V5d29yZD48a2V5d29yZD5SaXNrIEFzc2Vzc21lbnQvY2xhc3NpZmlj
YXRpb24vbWV0aG9kczwva2V5d29yZD48a2V5d29yZD5SaXNrIEZhY3RvcnM8L2tleXdvcmQ+PGtl
eXdvcmQ+VmVub3VzIFRocm9tYm9lbWJvbGlzbS9ldGlvbG9neS8gcHJldmVudGlvbiAmYW1wOyBj
b250cm9sPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMDg8L3llYXI+PHB1Yi1k
YXRlcz48ZGF0ZT5KdW48L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNDYwLTk1OTIg
KEVsZWN0cm9uaWMpJiN4RDsxMTU1LTU2NDUgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVt
PjE4NDQ1MjAwPC9hY2Nlc3Npb24tbnVtPjx1cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1yZXNvdXJj
ZS1udW0+MTAuMTExMS9qLjE0NjAtOTU5Mi4yMDA4LjAyNTk3Lng8L2VsZWN0cm9uaWMtcmVzb3Vy
Y2UtbnVtPjxyZW1vdGUtZGF0YWJhc2UtcHJvdmlkZXI+TkxNPC9yZW1vdGUtZGF0YWJhc2UtcHJv
dmlkZXI+PGxhbmd1YWdlPmVuZzwvbGFuZ3VhZ2U+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT5=
ADDIN EN.CITE.DATA 2,4:High risk paediatric surgical patientsA prior history of VTE not related to an intravenous linePaediatric patients with any four of the following identified risk factors:Age: less than 3 months, or older than 15 years, or post-pubertal. Significant co-morbidities – any infection, or inflammatory disease (e.g. inflammatory bowel disease, connective tissue diseases, Kawasaki disease, nephrotic syndrome) or congenital heart disease. Presence of cancer - this includes haematological cancer such as leukaemia. Severe injury – this includes chest injury, abdominal injury, limb fractures (particularly lower limb), head injury, multiple injuries etc. Major surgery – e.g. chest, abdominal, spinal, lower limb orthopaedic, craniotomy.Presence of a central venous catheter. Previous line-related VTE – i.e., thrombosis at the site of a central venous catheter or PICC line. “Oestrogenic states” – pregnancy, use of the oral contraceptive, or miscarriage /termination in the last 3 months. Known (or strongly suspected to have) Inherited thrombophilia (factor V Leiden gene mutation, prothrombin gene mutation, protein C deficiency, protein S deficiency, antithrombin deficiency, raised plasma factor VIII, raised plasma homocysteine) or antiphospholipid syndrome. High risk patients should be administered LMWH prophylaxis starting 6-12 hours post operatively, where there is adequate haemostasis. Enoxaparin is recommended in high risk patients at the following doses ADDIN EN.CITE <EndNote><Cite><Author>Westmead</Author><Year>2010</Year><RecNum>237</RecNum><DisplayText><style face="superscript">2</style></DisplayText><record><rec-number>237</rec-number><foreign-keys><key app="EN" db-id="pseax52au2spagesfz55ssrxezptref2pzex">237</key></foreign-keys><ref-type name="Government Document">46</ref-type><contributors><authors><author>The Children's Hospital at Westmead</author></authors><secondary-authors><author>NSW Health</author></secondary-authors></contributors><titles><title>THROMBOPROPHYLAXIS IN SURGICAL AND TRAUMA PAEDIATRIC PATIENTS 
PRACTICE GUIDELINE</title></titles><dates><year>2010</year></dates><publisher>NSW Health</publisher><urls></urls></record></Cite></EndNote>2:0.5mg/kg/dose bd ( to a maximum of 20mg bd) if ≥ 2 months old 0.75mg/kg/dose bd if < 2 months old It should be ceased when the patient is mobile or on discharge.Back to Table of ContentsImplementation Email notification to all medical staff Back to Table of ContentsRelated Policies, Procedures, Guidelines and LegislationProceduresCHHS Anticoagulation Management procedure, CHHS15/131Guidelines National Health and Medical Research Council “Blood Clots: Reducing your Risk” BrochureBack to Table of ContentsReferencesStein PD, Kayali F, Olson RE: Incidence of venous thromboembolism in infants and children: data from the National Hospital Discharge Survey. J Pediatr 145:563-5, 2004Westmead TCsHa: Thromboprophylaxis in surgical and trauma paediatric patients practice guideline, in Health n (ed), NSW health, 2010Vavilala MS, Nathens AB, Jurkovich GJ, et al: Risk factors for venous thromboembolism in pediatric trauma. J Trauma 52:922-7, 2002Jackson PC, Morgan JM: Perioperative thromboprophylaxis in children: development of a guideline for management. Paediatr Anaesth 18:478-87, 2008Back to Table of ContentsDefinition of Terms: AbbreviationsVTE - Venous thromboembolismLMWH - Low molecular weight heparinNIMC - National Inpatient Medication ChartBack to Table of ContentsSearch Terms Venous thrombosisPulmonary embolismVenous thromboembolismAnticoagulation Back to Table of ContentsAttachmentsAttachment 1: Venous Thromboembolism Prophylaxis GuidelinesAttachment 2: “Stop the Clot” Patient BrochureDisclaimer: This document has been developed by ACT Health, <Name of Division/ Branch/Unit> specifically for its own use. Use of this document and any reliance on the information contained therein by any third party is at his or her own risk and ACT Health assumes no responsibility whatsoever.Date AmendedSection AmendedApproved By05/08/2016Section 1CHHSPC ChairAttachment 1: Venous Thromboembolism Prophylaxis GuidelinesAttachment 2: “Stop the Clot” Patient Brochure ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- icu sedation guidelines
- anticoagulation management service guideline 07242016
- national pbm monograph template
- venous thromboembolism vte prevention
- q a xxxxxx sash surrey and sussex healthcare nhs trust
- acute spinal cord injury quadriplegia tetraplegia
- shared care protocol between sheffield teaching hospitals
Related searches
- venous thromboembolism symptoms
- what is venous thromboembolism vte
- vte prevention in hospital
- venous thromboembolism prevention
- venous thromboembolism risk factor assessment
- venous thromboembolism treatment
- venous thromboembolism guidelines
- venous thromboembolism vte
- venous thromboembolism signs and symptoms
- vte prevention guidelines
- venous thromboembolism pathophysiology
- venous thromboembolism vs dvt